Brooklyn ImmunoTherapeutics (BTX) – FDA
-
Brooklyn ImmunoTherapeutics (BTX) Reports Phase 2 Study of IRX-2 Did Not Reach Endpoint
-
Brooklyn ImmunoTherapeutics (BTX) Issues Update on Regenerative Medicine Intellectual Property Portfolio
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to BTX Stock Lookup